Relay Therapeutics (RLAY) Q3 2026 earnings review
Relay Therapeutics enrolls breast cancer patients faster, while trial costs rise
Relay Therapeutics, a drug developer targeting genetic mutations in cancer and blood-vessel disorders, signed up patients faster while spending more cash. Chief executive Sanjiv Patel said its lead late-stage breast cancer trial will finish enrollment in mid-2027, about a year ahead of industry benchmarks. Research costs rose 13% from a year ago to $77 million, and cash fell by $62 million to $849 million, right inside what the company's own plan pointed to.
| Cash and investments | $848.6M down $62.3M from last quarter |
|---|---|
| Research and development costs | $77.1M +13% from a year ago |
| Phase 3 breast cancer enrollment | Mid-2027 about 1 year ahead of benchmarks |
| Cash runway outlook | Unchanged funds operations into 2029 |
⚖️ Verdict: 🟢 Bullish
The story got better because clinical execution sped up on two fronts. Finishing breast cancer enrollment a year early pulls the main readout closer, and hiring commercial chief Shannon Campbell ahead of December's blood-vessel presentation shows preparation for regulatory talks. One caution: earlier stock sales lifted the share count by 27%, and starting a second late-stage breast cancer trial in early 2027 will push cash burn higher.
The question now is whether early blood-vessel data and three-drug cancer combinations can turn into registrational paths before the main breast cancer readout. One view sees them as independent shots on goal, while the other says only the ongoing second-line breast cancer study against an active rival decides the company's worth. Regulatory updates at the December 14 hematology meeting and by year-end will settle the trial designs.
🐂 Bull Case
Lead Breast Cancer Trial Enrolls One Year Early
Relay Therapeutics is testing its main experimental drug, zovegalisib, which blocks a mutated protein called PI3K alpha that helps tumors grow. Chief executive Sanjiv Patel said the team is pleased with enrollment in ReDiscover-2, a late-stage trial for second-line breast cancer patients. The drug developer now expects to finish signing up patients in mid-2027, which it called "approximately one year faster than recent benchmarks".
The company also plans a separate late-stage trial for first-line breast cancer starting in early 2027. That study combines zovegalisib with atirmociclib, a Pfizer pill that blocks a cell-division protein called CDK4. Patel pointed to recent Pfizer trial results, "which we believe showed the potential advantage of a CDK4-selective approach". Faster recruitment matters because it pulls the final readout closer without waiting on rivals.
What to watch: the regulatory update by the end of 2026 to confirm the first-line trial design. An agreement with regulators lets the biotech start that second major study in early 2027.
December Blood Conference Brings Vascular Update
Relay is also testing zovegalisib in vascular anomalies, which are genetic blood-vessel defects driven by the same PI3K alpha mutation. Doctors will present updated results from the early-stage ReInspire study at the American Society of Hematology meeting on December 14, 2026. The Cambridge company will host a call that day to discuss the data and give a regulatory update on the path forward.
To prepare for potential drug launches, the firm hired Shannon Campbell as head of commercial. Relay cited her record in "preparing organizations for the transition to commercial-stage operations" at Merus and Novartis, where her remit covered breast cancer and vascular anomalies. Bringing in a sales chief now shows confidence in the upcoming December regulatory talks.
What to watch: the regulatory update on December 14 after the medical presentation. Confirmation that the current trial can support an approval filing would make vascular anomalies the fastest path to market.
Partner Drug Approval Validates Discovery Platform
Relay uses a computer-driven drug discovery system called Dynamo to design molecules that hit mutated proteins while sparing healthy ones. In the third quarter, the Food and Drug Administration approved LYRFIGTU, a bile-duct cancer medicine originally discovered on that platform. Relay licensed global rights for the drug, also called lirafugratinib, to Elevar Therapeutics in December 2024.
The biotech recorded no license revenue in the third quarter, and $3.4 million over the first nine months of 2026. Still, LYRFIGTU is the first approved medicine to emerge from the Dynamo platform. The approval proves Relay's computer models can create drugs that pass regulatory review, and it opens the door to commercial milestone payments and royalties from Elevar.
What to watch: license and royalty revenue in the fourth-quarter report. A milestone payment for the regulatory approval or early sales royalties would help offset clinical trial costs.
🐻 Bear Case
Trial Expansion Lifts Cash Burn
Because Relay has no commercial products of its own, running larger clinical trials directly increases its losses. Total operating expenses rose 12.3% from a year ago to $90.2 million, widening the quarterly net loss by 10.2% to $81.7 million. Both research and administrative lines included "non-recurring costs related to the termination of the company’s operating lease at One Kendall Square".
- Research and development costs: $77.1 million, up 13.0% from a year ago
- General and administrative costs: $13.1 million, up 8.1% from a year ago
- Cash and investments: $848.6 million, down $62.3 million from last quarter by our math
Relay still expects its cash to fund operations "into 2029". By our math, spreading $848.6 million across the nine quarters before 2029 allows up to $94.3 million in quarterly burn, and the planned first-line breast cancer trial will push spending toward that ceiling.
What to watch: the exact cost of the One Kendall Square lease exit in the quarterly filing. If the one-off charge was small, ongoing trial spending is already running near $90 million a quarter.
Share Count Jumps 27% After Stock Sales
On a per-share basis, Relay's net loss looked smaller this quarter, narrowing to $0.37 from $0.43 a year ago. That improvement is an accounting effect of heavy stock issuance rather than lower spending. The total dollar loss actually grew by $7.6 million over the same period.
Weighted average shares climbed 27.1% from a year ago to 219.2 million, and rose 8.0% from the second quarter alone. The jump reflects the full-quarter count of shares sold in May's $316 million public offering and earlier at-the-market stock sales. In August, the biotech also expanded its at-the-market stock sales capacity to $463.0 million, leaving the door open for more dilution even with $848.6 million in the bank.
What to watch: fourth-quarter weighted average share count and any new stock sales in the quarterly filing. Any share issuance while cash sits above $800 million would dilute existing owners ahead of clinical readouts.
Risks this quarter didn't answer
Several clinical and pipeline concerns received no new data in the third-quarter update, and the company pushed one readout timeline slightly further out.
- Three-drug breast cancer combination data: now listed for 2027 rather than the first half of 2027, leaving open how earlier unoptimized doses will perform.
- Late-stage breast cancer trial risk: ReDiscover-2 enrollments are moving fast, but the drug still has to beat an active rival treatment when results arrive after mid-2027.
- Early pipeline progress: the release mentioned NRAS solid tumor and Fabry disease programs in passing, with no clinical timeline for the delayed Fabry candidate.
👓 Other Themes
Second Vascular Program Enters Preclinical Pipeline
Relay unveiled a new research program targeting TIE2, a protein whose mutation causes venous malformations in 50,000 to 60,000 Americans. Existing drugs block both healthy and mutated TIE2, which can cause severe eye toxicity. The biotech credits its platform with "discovering the first known mutant-selective TIE2 inhibitor", now in late-stage preclinical testing to avoid those side effects.
💲 Other KPIs
Interest earned on cash reserves rose 32.7% from a year ago and 19.5% from the second quarter. The increase follows May's $316 million stock offering, which boosted the investment balance for the full three months and covered nearly a tenth of quarterly operating costs.
Working capital — short-term assets minus short-term bills — fell 8.2% from the second quarter as Relay spent cash on clinical trials. Compared with a year ago, the buffer is still up 36.2% thanks to stock sales in the first half of 2026.
Total liabilities — money owed for clinical trials, leases and operations — climbed 32.8% from a year ago and 6.8% from last quarter. The build-up tracks the faster pace of patient enrollment in the Phase 3 breast cancer study and the One Kendall Square lease exit.
🔮 Guidance
Unchanged. Relay still expects its $848.6 million in cash and investments to fund operations into 2029. By our math, that leaves an average quarterly burn ceiling of about $94.3 million over the next nine quarters, compared with the $62.3 million cash drop in the third quarter. It is the seventh straight quarter the biotech has given the 2029 date.
❓ Key Questions
How much did the One Kendall Square lease exit cost?
Both research and administrative expenses included one-off lease termination charges this quarter. Knowing the exact dollar figure shows how much of the $90.2 million operating spend came from ongoing clinical trials.
Did Relay receive a milestone for the LYRFIGTU approval?
Partner Elevar won FDA approval for lirafugratinib, which carries up to $485 million in potential milestone payments. Management did not say whether the approval triggered an immediate cash payout in the fourth quarter.
Why did the three-drug breast cancer readout slip to 2027?
Last quarter's milestone table pointed to a data update for the three-drug combination in the first half of 2027, while this release says 2027. Clarifying the timing matters because the Phase 3 first-line study starts in early 2027.
How much will the first-line breast cancer trial cost?
Starting a second Phase 3 study in early 2027 will lift research spending, even with Pfizer supplying two of the drugs. Investors need the trial's budget to judge how far into 2029 the $848.6 million cash pile reaches.